Greene LM - Search Results

1

Synthesis and Biochemical Evaluation of 3-Phenoxy-1,4-diarylazetidin-2-ones as Tubulin-Targeting Antitumor Agents.

Greene TF, Wang S, Greene LM, Nathwani SM, Pollock JK, Malebari AM, McCabe T, Twamley B, O'Boyle NM, Zisterer DM, Meegan MJ. Greene TF, et al. Among authors: greene lm. J Med Chem. 2016 Jan 14;59(1):90-113. doi: 10.1021/acs.jmedchem.5b01086. Epub 2015 Dec 17. J Med Chem. 2016. PMID: 26680364

2

Selective induction of apoptosis by the pyrrolo-1,5-benzoxazepine 7-[[dimethylcarbamoyl]oxy]-6-(2-naphthyl)pyrrolo-[2,1-d] (1,5)-benzoxazepine (PBOX-6) in Leukemia cells occurs via the c-Jun NH2-terminal kinase-dependent phosphorylation and inactivation of Bcl-2 and Bcl-XL.

Mc Gee MM, Greene LM, Ledwidge S, Campiani G, Nacci V, Lawler M, Williams DC, Zisterer DM. Mc Gee MM, et al. Among authors: greene lm. J Pharmacol Exp Ther. 2004 Sep;310(3):1084-95. doi: 10.1124/jpet.104.067561. Epub 2004 May 13. J Pharmacol Exp Ther. 2004. PMID: 15143129

3

The pyrrolo-1,5-benzoxazepine, PBOX-6, inhibits the growth of breast cancer cells in vitro independent of estrogen receptor status and inhibits breast tumour growth in vivo.

Greene LM, Fleeton M, Mulligan J, Gowda C, Sheahan BJ, Atkins GJ, Campiani G, Nacci V, Lawler M, Williams DC, Zisterer DM. Greene LM, et al. Oncol Rep. 2005 Nov;14(5):1357-63. Oncol Rep. 2005. PMID: 16211309

4

Identification of tubulin as the molecular target of proapoptotic pyrrolo-1,5-benzoxazepines.

Mulligan JM, Greene LM, Cloonan S, Mc Gee MM, Onnis V, Campiani G, Fattorusso C, Lawler M, Williams DC, Zisterer DM. Mulligan JM, et al. Among authors: greene lm. Mol Pharmacol. 2006 Jul;70(1):60-70. doi: 10.1124/mol.105.021204. Epub 2006 Mar 29. Mol Pharmacol. 2006. PMID: 16571652

5

STI-571 (imatinib mesylate) enhances the apoptotic efficacy of pyrrolo-1,5-benzoxazepine-6, a novel microtubule-targeting agent, in both STI-571-sensitive and -resistant Bcr-Abl-positive human chronic myeloid leukemia cells.

Greene LM, Kelly L, Onnis V, Campiani G, Lawler M, Williams DC, Zisterer DM. Greene LM, et al. J Pharmacol Exp Ther. 2007 Apr;321(1):288-97. doi: 10.1124/jpet.106.116640. Epub 2007 Jan 3. J Pharmacol Exp Ther. 2007. PMID: 17202400

6

BubR1 is required for a sustained mitotic spindle checkpoint arrest in human cancer cells treated with tubulin-targeting pyrrolo-1,5-benzoxazepines.

Greene LM, Campiani G, Lawler M, Williams DC, Zisterer DM. Greene LM, et al. Mol Pharmacol. 2008 Feb;73(2):419-30. doi: 10.1124/mol.107.039024. Epub 2007 Nov 8. Mol Pharmacol. 2008. PMID: 17991869

7

The novel pyrrolo-1,5-benzoxazepine, PBOX-21, potentiates the apoptotic efficacy of STI571 (imatinib mesylate) in human chronic myeloid leukaemia cells.

Bright SA, Greene LM, Greene TF, Campiani G, Butini S, Brindisi M, Lawler M, Meegan MJ, Williams DC, Zisterer DM. Bright SA, et al. Among authors: greene lm, greene tf. Biochem Pharmacol. 2009 Feb 1;77(3):310-21. doi: 10.1016/j.bcp.2008.10.008. Epub 2008 Oct 30. Biochem Pharmacol. 2009. PMID: 19014913

8

The novel tubulin-targeting agent pyrrolo-1,5-benzoxazepine-15 induces apoptosis in poor prognostic subgroups of chronic lymphocytic leukemia.

McElligott AM, Maginn EN, Greene LM, McGuckin S, Hayat A, Browne PV, Butini S, Campiani G, Catherwood MA, Vandenberghe E, Williams DC, Zisterer DM, Lawler M. McElligott AM, et al. Among authors: greene lm. Cancer Res. 2009 Nov 1;69(21):8366-75. doi: 10.1158/0008-5472.CAN-09-0131. Epub 2009 Oct 13. Cancer Res. 2009. PMID: 19826055 Free article.

9

Lead identification of conformationally restricted benzoxepin type combretastatin analogs: synthesis, antiproliferative activity, and tubulin effects.

Barrett I, Carr M, O'Boyle N, Greene LM, Knox AJ, Lloyd DG, Zisterer DM, Meegan MJ. Barrett I, et al. Among authors: greene lm. J Enzyme Inhib Med Chem. 2010 Apr;25(2):180-94. doi: 10.3109/14756360903169659. J Enzyme Inhib Med Chem. 2010. PMID: 20222762

10

The vascular targeting agent combretastatin-A4 and a novel cis-Restricted {beta}-Lactam Analogue, CA-432, induce apoptosis in human chronic myeloid leukemia cells and ex vivo patient samples including those displaying multidrug resistance.

Greene LM, Nathwani SM, Bright SA, Fayne D, Croke A, Gagliardi M, McElligott AM, O'Connor L, Carr M, Keely NO, O'Boyle NM, Carroll P, Sarkadi B, Conneally E, Lloyd DG, Lawler M, Meegan MJ, Zisterer DM. Greene LM, et al. J Pharmacol Exp Ther. 2010 Nov;335(2):302-13. doi: 10.1124/jpet.110.170415. Epub 2010 Aug 10. J Pharmacol Exp Ther. 2010. PMID: 20699436

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

43 results

Search Page